Atrion in $24.5 million deal for Quest cardiovascular lines
This article was originally published in Clinica
Atrion has agreed to buy Quest Medical's cardiovascular and intravenous fluid delivery product lines for $24.5 million in cash. Atrion will also get Quest's 27 patents relating to the products and will lease Quest's factory in Texas where the products are made - with an option to buy the plant for a further $6.5 million.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.